2014 Chrysler Town & Country Touring-l on 2040-cars

Auto blog

2018 Chrysler Pacifica Hybrid Long-Term Update | Recall!

Our long-term 2018 Chrysler Pacifica Hybrid has been in the fleet for about six months now and is quickly accumulating more miles than most of our long-term vehicles do in a full year. Thanks to a couple of recent road trips, one to New England and one to Florida, our Ocean Blue Metallic minivan has racked up about 15,000 miles. I personally hope we can cross the 25,000-mile mark before we're finished. The Pacifica Hybrid has garnered near universal praise from the Autoblog staff, especially those of us who have kids or pets. While it's mostly been hiccup free, one recall had us a bit on edge. NHTSA campaign number 18V740000 was issued last fall, but we didn't get the notification until early this year. Blame the delay on the weird ownership situation of long-term vehicles. NHTSA's basic description is short. "After the vehicle has been operating in PHEV propulsion mode, the gas-fueled engine may not restart properly resulting in unburned fuel entering the exhaust catalyst." Basically, the engine may not restart correctly after running in EV mode, and the fuel being fed to the engine could make its way past the exhaust manifold to the catalytic converters and ignite, possibly starting a fire. Obviously, that's bad. We scheduled a visit to the dealer as soon as we got the news. Chrysler's fix is to update the computer, visually inspect the cats and replace them if needed. We hadn't noticed any issues with the Pacifica's powertrain, and the inspection came back clean, so our Pacifica was back in our hands in a few hours. The service sheet says the left and right cats were inspected by borescope and the powertrain control module was updated. All in, the Pacifica was out of our hands for about half a day. Related Video:

Mopar Hellephant crate engine sells out in 48 hours

This happened so quickly that we're only just catching up with it. Mopar opened pre-orders on the 7.0-liter Hellephant Hemi crate engine on April 26, which is Hemi Day. According to Allpar, hubbub on social media not long after that day claimed Mopar had gone through all of its Hellephant stock. When Allpar asked Fiat Chrysler for clarification, a spokesperson e-mailed, "Given the high demand and the hand-built, time-intensive build process, we have closed preordering for the 426 Hellephant Supercharged HEMI crate engine. Based on preorders, the engine sold out in just two days. Customers can visit www.cratehemi.com to receive future information and updates on the 'Hellephant' engine." No one is certain how many engines Mopar sold. Allpar wrote, "Industry insiders believe Mopar may be making around 100," but reiterated that it's a guess. The engine and the ordering process have their peculiarities. Mopar Insiders explained that Tool Engineering International helped create the 426-cubic-inch block, and that the Hellephant engine "shares nothing except for displacement with the rumored upcoming 7.0-liter 426 Hemi V8." On the Hellcat.org forum, a poster wrote that the engines "can only be sold through a dealer and that the dealers can only order 1 engine per week." The Hellephant doesn't come with Mopar's three-year, 100,000-mile warranty, either. During a press briefing last October, FCA officials said they weren't sure about offering any warranty. Based on the motor being given a part number starting with the letter P, there is a bit of protection, but it's a 90-day limited warranty covering "defects in materials or wokmanship," and only applies to engines not used in competition. For those who didn't get the opportunity to drop $29,995 for 1,000 horsepower and 950 pound-feet of torque, the best bet is to hope for the return of Apollyon's pachyderm. Motor1 wrote that "Rumors hint at... another limited run scheduled for next year due to overwhelming demand." That's thin thread to hang a Hellephant from, but it beats bupkis.

Fiat Chrysler says it did not know about Marchionne's illness

ZURICH/MILAN — Fiat Chrysler said it knew nothing about the medical condition of Sergio Marchionne after a Swiss hospital said on Thursday it had been treating the deceased chief executive for more than a year. "Due to medical privacy, the company had no knowledge of the facts relating to Mr. Marchionne's health," a Fiat Chrysler spokesman said. Questions have been raised about how long Marchionne, who died on Wednesday, was ill and how much the company knew before it made the situation public. Marchionne rescued Fiat and Chrysler from bankruptcy after taking the wheel of the Italian carmaker in 2004 and he multiplied Fiat's value 11 times through 14 years of canny dealmaking. He was due to step down at FCA in April next year. "The company was made aware that Mr. Marchionne had undergone shoulder surgery and released a statement about this," the spokesperson said. "On Friday, July 20, the company was made aware with no detail by Mr. Marchionne's family of the serious deterioration in Mr. Marchionne's condition and that as a result he would be unable to return to work. The company promptly took and announced the appropriate action the following day." Asked whether the scope of the statement included the board and the chairman, the company declined to comment. In emailed comments, Marchionne's family confirmed the companies had not been aware of his health conditions. "At the end of last week FCA was made aware Sergio Marchionne would no longer be able to return to work without mentioning any further details," the family said. The announcement of the death of Marchionne, 66, one of the auto industry's most tenacious and respected CEOs, drew tributes from rivals and tears from his closest colleagues on Wednesday. University Hospital Zurich said earlier on Thursday Marchionne had been treated for a serious illness for more than a year before his death. Marchionne had fallen gravely ill after what the company had described as shoulder surgery at a Zurich hospital. He was replaced as chief executive last weekend after Fiat Chrysler (FCA) said his condition had worsened. "Mr. Sergio Marchionne was a patient at USZ. Due to serious illness, he had been the recipient of recurring treatment for more than a year," the hospital said in a statement. "Although all the options offered by cutting-edge medicine were utilized, Mr.